# CheckMate-032 (NCT01928394)

> A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus ipilimumab; nivolumab plus ipilimumab plus cobimetinib
- Indication: advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01928394
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Advanced or Metastatic Solid Tumors
- Interventions: Nivolumab; Ipilimumab; Cobimetinib
- Enrollment: 1163
- Primary outcome: Objective Response Rate ( ORR )

## Indexed commentary on CheckMate-032 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 19
- YouTube: 7
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-032-nct01928394

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01928394", "email": "<work email>"}; the inbox owner confirms by the emailed link.